Susan Halabi, PhD, FSCT, FASA, FASCO, Duke University Medical Center, Durham, NC, highlights the impact of genetic variants such as PTEN loss, RB1 loss, and AR gain on overall survival (OS) in metastatic castrate-resistant prostate cancer (mCRPC). Future clinical trials are anticipated to target these specific genetic alterations to improve patient prognosis and outcomes, similar to the use of PARP inhibitors in patients with breast cancer who have BRCA mutations. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Ещё видео!